The aberrant activation of EGFR leads to the triggering of downstream signaling cascades, including the Ras/Raf/MEK/ERK, PI3K-AKT and JAK/STAT pathways, which contribute to tumor progression, metastasis and therapeutic resistance [21,22]. Here, AKT1 is linked to neoplasm.